Bora Pharmaceuticals Co (TPE:6472) Total Receivables: NT$9,604 Mil (As of Dec. 2025)


TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
87 GF Score
Price NT$425.50
GF Value NT$718.20
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co Total Receivables?

Bora Pharmaceuticals Co TPE:6472 -1.05% 87 Total Receivables is NT$9,604 Mil as of Dec. 2025. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$718.20 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Bora Pharmaceuticals Co's Total Receivables for the quarter that ended in Dec. 2025 was NT$9,604 Mil.

Bora Pharmaceuticals Co Total Receivables Related Terms

Bora Pharmaceuticals Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co Total Receivables Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 858.01 6,406.52 4,110.92 11,247.88 9,604.48

Bora Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,247.88 10,823.94 8,460.92 8,979.81 9,604.48
TPE:6472
87GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bora Pharmaceuticals Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$9,604 Mil mean?
Bora Pharmaceuticals Co (TPE:6472) has a Total Receivables of NT$9,604 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bora Pharmaceuticals Co and its competitors.
Is Bora Pharmaceuticals Co's Total Receivables too high?
Bora Pharmaceuticals Co's current Total Receivables is NT$9,604 Mil. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Total Receivables compare to ZTS and UTHR?
Bora Pharmaceuticals Co's Total Receivables of NT$9,604 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Total Receivables is NT$9,604 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$718.20, compared to a current price of NT$425.50 — trading 40.8% below its estimated fair value. The current Total Receivables is NT$9,604 Mil. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Total Receivables is NT$9,604 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$425.50 is trading 40.8% below its estimated GF Value™ of NT$718.20. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • Total Receivables: NT$9,604 Mil
  • GF Value™: NT$718.20 vs. price of NT$425.50 (40.8% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bora Pharmaceuticals Co Business Description

Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score

Get the complete analysis for TPE:6472

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$425.50
Price
NT$718.20
GF Value